Feasibility of anti-VEGF agent bevacizumab in patients with Crohn's disease

Inflammatory Bowel Diseases

Volumn 17, Issue 7, 2011, Pages 1632-

  Coriat, Romain ^a,b   Mir, Olivier ^a   Leblanc, Sarah ^b   Ropert, Stanislas ^a   Brezault, Catherine ^b   Chaussade, Stanislas ^b   Goldwasser, François ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Institut Cochin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CORTICOSTEROID; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MESALAZINE; OXALIPLATIN; SORAFENIB; SUNITINIB;

ADULT; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CASE REPORT; COLON CARCINOMA; COLON RESECTION; COLONOSCOPY; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LETTER; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RECTUM CARCINOMA; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COLONIC NEOPLASMS; CROHN DISEASE; FEASIBILITY STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RECTAL NEOPLASMS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79958842222     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21545     Document Type: Letter

References (7)

1. Weedon DD, Shorter RG, Ilstrup DM, et al. Crohn's disease and cancer. N Engl J Med. 1973; 289: 1099-1103.
2. Winawer SJ, Schottenfeld D, Flehinger BJ,. Colorectal cancer screening. J Natl Cancer Inst. 1991; 83: 243-253.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342. (Pubitemid 38702844)
4. Loriot Y, Boudou-Rouquette P, Billemont B, et al. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. Ann Oncol. 2008; 19: 1975.
5. Ducreux M, Bennouna J, Hebbar M, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer. 2010 [Epub ahead of print].
6. Krzystek-Korpacka M, Neubauer K, Matusiewicz M,. Platelet-derived growth factor-BB reflects clinical, inflammatory and angiogenic disease activity and oxidative stress in inflammatory bowel disease. Clin Biochem. 2009; 42: 1602-1609.
7. Kumagai S, Ohtani H, Nagai T, et al. Platelet-derived growth factor and its receptors are expressed in areas of both active inflammation and active fibrosis in inflammatory bowel disease. Tohoku J Exp Med. 2001; 195: 21-33. (Pubitemid 34036883)